MDxHealth (NASDAQ:MDXH) Issues Quarterly Earnings Results

MDxHealth (NASDAQ:MDXH) announced its quarterly earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07, Zacks reports. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%.

MDxHealth Trading Down 6.2 %

NASDAQ:MDXH traded down $0.12 during mid-day trading on Wednesday, hitting $1.83. 97,573 shares of the company’s stock were exchanged, compared to its average volume of 102,566. The firm has a market capitalization of $86.54 million, a P/E ratio of -1.20 and a beta of 1.34. The company has a 50 day simple moving average of $2.02 and a 200-day simple moving average of $2.20. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. MDxHealth has a fifty-two week low of $1.55 and a fifty-two week high of $3.85.

Wall Street Analyst Weigh In

Several research analysts recently commented on MDXH shares. Piper Sandler reduced their target price on MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Lake Street Capital started coverage on shares of MDxHealth in a research note on Thursday, October 31st. They set a “buy” rating and a $7.00 price objective on the stock.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.